Paeds · genetics-dysmorphology-and-metabolism
Lysosomal storage disorders
Also known as Lysosomal storage disorders · Lysosomal storage diseases · LSDs · Inborn errors of lysosomal metabolism · Sphingolipidoses
A fellowship approach to the lysosomal storage disorders: recognise the clinical phenotypes that trigger the search (developmental regression with organomegaly, coarse facies, or cardiomyopathy), group them by stored substrate, confirm with a layered enzyme-and-genotype workup, and match the disease-modifying therapy — enzyme replacement, substrate reduction, or haemopoietic stem cell transplant — to whether the central nervous system is involved.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child who was developing normally then loses motor or language milestones, with a large liver or spleen, has a lysosomal storage disorder until enzyme assays prove otherwise
- Hypertrophic cardiomyopathy with hypotonia and weak reflexes in an infant is Pompe disease (acid maltase deficiency) until dried-blood-spot GAA activity is back
- An irritable, febrile infant with rigid extremities, feeding difficulty and rapid head growth may have infantile Krabbe disease — a disorder where the transplant window closes within weeks
- Coarse facies, corneal clouding, dysostosis multiplex and hepatosplenomegaly in a toddler points to a mucopolysaccharidosis, most often MPS I (Hurler)
- Episodic burning pain in the extremities, angiokeratomata, and anhidrosis in a boy is Fabry disease; check for proteinuria and left-ventricular wall thickening
- A cherry-red spot at the macula in a hypotonic, startle-prone infant signals Tay–Sachs or another gangliosidosis
- An abnormal newborn bloodspot screen for Krabbe, Pompe or MPS I demands immediate confirmatory testing — disease-modifying therapy is most effective before symptoms begin
Life stages
Care settings
Clinical exam formats
Board mappings
- General and Community Paediatrics
- Growth and Development
- Genetics and Metabolism
- Neurology - recognise and investigate neurodegenerative disorders and lysosomal storage diseases
- Metabolic Medicine - diagnose and manage lysosomal storage disorders
- Cardiology - recognise infiltrative cardiomyopathy including Pompe and Fabry disease
- Metabolic Medicine 1-3
- Neurology 13-15
- Clinical Applications
- Long Cases
- Short Cases
- 2. Genetics: chromosomal and multi-system disorders
- 8. Metabolic medicine: inborn errors of metabolism
- 9. Neurology: neurodegenerative disorders
- Foundation of Practice (FOP)
- Theory and Science (TAS)
- Applied Knowledge in Practice (AKP)
- Clinical
- Development
- Communication
- History
- General Pediatrics Content Outline - D19 Genetics (6%)
- General Pediatrics Content Outline - D21 Metabolic Disorders (3%)
- General Pediatrics Content Outline - D15 Neurology (6%)
- Patient Care 4: Clinical Reasoning
- Patient Care 5: Patient Management
- Medical Knowledge 1: Congenital and Genetic Disorders
- Systems-Based Practice 1: Patient Safety
- Medical Expert
- Pediatrics: Metabolic Medicine
- Pediatrics: Neurology - neurodegenerative disease
A four-month-old who had been smiling and rolling stops meeting milestones, grows irritable, and is found at the six-month check to have a liver edge five centimetres below the costal margin and spastic limbs. Across the corridor, a newborn bloodspot screen flags low galactocerebrosidase activity, and the clock starts on whether a transplant can be arranged before the demyelination becomes irreversible. In both rooms the unifying question is the same: which lysosomal enzyme is missing, how fast is it injuring the brain, and what can be done before the damage is permanent. The fellowship task is to reason from phenotype to substrate to therapy without losing time. [3] [6]
Work the bedside-to-lab path with LYSOSOME — Liver and spleen (hepatosplenomegaly from stored material in macrophages), Young regression (loss of motor or language milestones), Skeletal change (dysostosis multiplex, short stature, coarse facies), Ophthalmic signs (cherry-red spot, corneal clouding), Stiff heart (hypertrophic cardiomyopathy in Pompe, Fabry, Danon), Orphan enzyme (confirm with leucocyte assay then genotype), Match the modality (ERT for viscera, HSCT for the brain, SRT or chaperone to bridge), and Early matters most (transplant and enzyme outcomes hinge on pre-symptomatic treatment). [1] [11]
Overview & Definition
The lysosome is the cell's recycling organelle — an acidic compartment packed with hydrolases that break down macromolecules into building blocks the cell can reuse. A lysosomal storage disorder is what happens when one link in that degradative chain fails: the enzyme is absent or misfolded, its substrate cannot be cleaved, and undegraded material accumulates progressively inside the lysosome until the cell distends, malfunctions, and dies. The stored material, not the missing enzyme per se, drives the visible phenotype, which is why a Gaucher macrophage engorged with glucocerebroside looks and behaves differently from a neuron swollen with ganglioside. [1] [4]
Although each disorder maps to a different enzyme and substrate, the clinical consequences follow recurring themes because lysosomes exist in almost every cell. Macrophage-rich organs enlarge, giving the hepatosplenomegaly that is the single most useful physical sign. The central nervous system bears the brunt in the neuronopathic forms, where stored substrate triggers neuroinflammation, demyelination, and neuronal loss. Bone, connective tissue, heart valves, and airways suffer in the disorders that store glycosaminoglycans or glycogen. Recognising that the same mechanism produces different patterns in different tissues is the conceptual hinge of the whole topic. [1] [2]
The inheritance matters because it changes counselling and screening. Most lysosomal storage disorders are autosomal recessive, so a previously affected child reshapes the reproductive risk for every subsequent pregnancy and makes carrier testing and prenatal diagnosis central to management. A small but high-yield group is X-linked — Fabry, Hunter syndrome (MPS II), and Danon disease — where affected boys present with disease and carrier mothers may show attenuated features. Naming the inheritance at the first consultation frames every later conversation about siblings, future children, and the wider family. [2] [3]
References11ShowHide
- [1]Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers, 2018.PMID 30275469
- [2]Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med, 2015.PMID 25587658
- [3]Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics, 2009.PMID 19336380
- [4]Boustany RM. Lysosomal storage diseases--the horizon expands. Nat Rev Neurol, 2013.PMID 23938739
- [5]Wenger DA, Rafi MA, Luzi P. Krabbe disease: One hundred years from the bedside to the bench to the clinic. J Neurosci Res, 2016.PMID 27638583
- [6]Kwon JM, Matern D, Kurtzberg J, et al. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis, 2018.PMID 29391017
- [7]Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med, 2006.PMID 16702877
- [8]Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford), 2011.PMID 22210669
- [9]Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics, 2007.PMID 17671068
- [10]Parenti G, Moracci M, Fecarotta S, et al. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem, 2014.PMID 25068986
- [11]Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. Semin Perinatol, 2015.PMID 25891428